Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
GH Research ( (GHRS) ) has provided an announcement.
On May 14, 2026, GH Research PLC filed a Form 6-K in the United States reporting its first-quarter 2026 results and providing business updates, alongside posting an updated investor presentation. The filing also furnished unaudited condensed consolidated interim financial statements for the three months ended March 31, 2026 and management’s discussion and analysis, signalling ongoing transparency for shareholders despite a first-quarter loss of $18.97 million versus $10.81 million a year earlier.
The company’s loss was driven by higher research and development and general and administrative expenses, which rose to $12.38 million and $6.37 million respectively, while finance income, foreign exchange movements and marketable securities valuations only partially offset the operating deficit. Comprehensive loss for the period widened to $18.23 million, though the continued provision of detailed XBRL-tagged disclosures and incorporation of the 6-K into existing registration statements underlines GH Research’s intent to support regulatory compliance and investor analysis as it advances its programs.
The most recent analyst rating on (GHRS) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.
Spark’s Take on GHRS Stock
According to Spark, TipRanks’ AI Analyst, GHRS is a Neutral.
The score is held back primarily by weak financial performance (no revenue, widening losses, and ongoing cash burn), partly offset by a strong, low-leverage balance sheet. Technicals are supportive with clear upward trend and positive momentum, while valuation remains a drag due to negative earnings and no dividend.
To see Spark’s full report on GHRS stock, click here.
More about GH Research
GH Research PLC is an Ireland-based biopharmaceutical company focused on developing novel therapies, with its shares registered in the United States as a foreign private issuer. The company reports under Form 20-F and maintains multiple U.S. shelf and employee share registration statements, reflecting its access to international capital markets.
Average Trading Volume: 216,444
Technical Sentiment Signal: Buy
Current Market Cap: $1.48B
See more data about GHRS stock on TipRanks’ Stock Analysis page.